Influenza vaccine development is considered to be complicated and challenging. Constantly evolving influenza viruses require continuous global monitoring and reformulation of the vaccine strains. Peptides that are conserved among different strains and subtypes of influenza A virus are strongly considered to be attractive targets for development of cross protective influenza vaccines that stimulate cellular responses. In this study, three highly conserved (>90%) matrix 1 peptides that contain multiple T cell epitopes, ILGFVFTLTVPSERGLQRRRF (P M 1), LIRHENRMVLASTTAKA (P M 2) and LQAYQKRMGVQMQR (P M 3), were assessed for their immunogenic potential in vitro by subjecting peripheral blood mononuclear cells from healthy volunteers to repetitive stimulation with these chemically synthesised peptides and measuring their IFN-g concentrations, proliferation by ELISA, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, respectively. Seven samples were screened for immunogenicity of P M 1 and P M 2, and six for that of P M 3. All six samples had positive responses (IFN-g secretion) to P M 3 stimulation, as did five and three for P M 2 and P M 1 respectively. In contrast, seven (P M 1 and P M 2) and four (P M 3) samples showed proliferative response as compared with unstimulated cells. The encouraging immunogenic response generated by these highly conserved matrix 1 peptides indicates they are prospective candidates for development of broadly reactive influenza vaccines.
There have been two pandemics of H1N1 influenza in the last 100 years, namely the Spanish flu in 1918 and swine flu in 2009. H1N1 has been the most prevalent subtype of influenza virus responsible for significant morbidity and mortality globally in humans. Taken together, annual epidemics of all the subtypes of influenza A virus that infect humans result in about 3 to 5 million cases of severe illness and about 0.25 to 0.50 million deaths worldwide (1) . Prophylaxis of influenza is still a subject for debate despite the collaborative efforts of researchers and medical professionals around the world towards its control. Vaccination is considered to be one of the most successful interventions ever introduced in the field of public health. Various vaccination strategies based on specific influenza virus strains are currently available for protecting against influenza. Nevertheless, recurrent mutations enable the influenza virus to escape the host's immune surveillance and cause disease.
The currently available inactivated influenza vaccine (trivalent influenza vaccine) elicits humoral immune response predominantly against HA. However, frequent mutations in the surface glycoprotein result in failure of existing antibodies to neutralize unmatched strains. Thus, a vaccine approach based on highly conserved regions of influenza virus proteins is of considerable importance. T cells have a major role in controlling influenza virus infection and its eventual clearance (2) . Cell-mediated immunity targets both surface (structural) and internal (non-structural) influenza proteins and can provide substantial crossreactivity. Cellular immunity is directed against the epitopes that are likely to be shared among various strains and subtypes of influenza A virus, thus making it ideal for the development of broadly reactive influenza vaccines (3) .
Matrix 1 protein is one of three proteins coded by the seventh segment of the influenza A virus genome. M2 ion channel and M42 are other two splice variants coded by the same segments (4) . Being an internal protein, M1 has a very low rate of mutation compared with surface proteins and would therefore likely be a less immunogenic protein than these proteins (5, 6) . However studies conducted in recent years have clearly demonstrated the prospects of M1 protein in combination with other influenza proteins as potential targets for development of a universal influenza vaccine (7) (8) (9) . In one study, mice vaccinated with recombinant vaccinia virus expressing the M1 protein were protected after challenge with a lethal dose of influenza virus A Puerto Rico/8/1934 H1N1 strain (10) . Similarly, significant humoral response was observed in mice immunised with Pichia pastoris expressing rHA and rM (11) .
Peptides from highly conserved M1 protein may be capable of conferring cross-protective immunity against present and future outbreaks of influenza to a large proportion of the world population. In our previous work on M1 protein, conserved peptides containing multiple T cell epitopes were identified by an immunoinformatics approach (12) . The three M1 peptides, ILGFVFTLTVPSERGLQRRRF (P M 1), LIRHENRMV-LASTTAKA (P M 2) and LQAYQKRMGVQMQR (P M 3), selected for the present work are highly conserved in seasonal and pandemic strains of H1N1, H3N2 and H2N2 (12) . These three synthetic M1 peptides were evaluated for their immunogenicity in vitro by an MTTbased lymphocyte proliferation assay and IFN-g ELISA.
MATERIALS AND METHODS

Prediction of peptide allergenecity and toxicity
Allergenicity of the three M1 peptides was predicted using the online tool AlgPred, which is based on screening IgE epitopes in query protein sequence and Motif Alignment & Search Tool (13) . An expressed protein/peptide is designated as a potential allergen if it possesses 35% identity using a window of 80 amino acids or has six contiguous amino acids with an established allergen (14) .
Therapeutics peptides are often associated with toxicity towards eukaryotic cells. ToxinPred is an in silico tool that helps in screening and identifying toxic peptides in a dataset of non-toxic or random peptides obtained from SwissProt and the translation of EMBL nucleotide sequence databases (15) .
Synthesis of peptides
P M 1, P M 2 and P M 3 peptides were commercially synthesised by GenScript (Piscataway, NJ, USA) and GL Biochem (Shanghai, China) with a purity !93%. The peptides were dissolved in sterile MilliQ water at a concentration of 1 mg/mL and stored in small aliquots at À20°C.
Blood sampling from healthy volunteers
Healthy human volunteers aged 18 years or older with no active hepatitis B, C, and/or HIV infection were included in the study. Blood (8 mL) was drawn by trained technicians from the Lifeline Blood Bank, Patiala and Nitin Hospital, Patiala, India. All the volunteers gave their informed consent to donate blood for the experiments and the study was approved by the institutional ethics committee.
Isolation of PBMC
Peripheral blood mononuclear cells were isolated by a Ficoll density gradient method. Whole blood was carefully layered onto Histopaque-1077 (Sigma-Aldrich, St Louis, MO, USA) and centrifuged at 400 g for 30 min at room temperature. After centrifugation, the upper plasma layer was carefully discarded by using a micropipette and the opaque interface (buffy coat) containing PBMC collected in a sterile conical centrifuge tube. The cells were washed twice (10 min each) with isotonic PBS solution. Finally, the cell pellets were resuspended in 1 mL of complete media (RPMI-1640 supplemented with 10% FBS, 100 mg/mL streptomycin, 100 I.U./mL penicillin and 10 mM 4-[2-hydroxyethyl]-1-piperazineethanesulfonic acid).
PBMC stimulation assay
Freshly isolated healthy PBMC were cultured with individual peptides to test their immunogenic potential (16) . Cells (2 Â 10 6 ) were stimulated with each individual peptide (25 mg/mL) in 24-well flat bottom cell culture plates in the presence of recombinant IL-2 (20 ng/mL) and complete media in a total volume of 2 mL (Day 1). Unstimulated cells were supplemented with complete media and IL-2. The plates were incubated at 37°C in a humidified incubator maintained at 5% CO 2 (New Brunswick Galaxy; Eppendorf, Hauppauge, NY, USA). On Days 4 and 7, the cultures were re-stimulated by replacing media with 1 mL fresh complete media containing the same concentrations of peptide and IL-2. On Day 10, peptide stimulated and unstimulated cells were harvested and recounted for further assessment of peptide specific IFN-g production and proliferative responses.
Measurement of INF-g
To investigate secretion of IFN-g by peptide-stimulated T cells, the cells harvested on the 10th day were seeded again in triplicates in 96-well plates at 1 Â 10 5 cells per well in total volumes of 200 mL. Cells recovered from unstimulated wells were distributed in two set of triplicates; one set stimulated with 10 mg/mL of concanavalin A (Sigma-Aldrich) served as a positive control, whereas the other set with unstimulated cells served as a negative control. Peptide-stimulated cells were given a final stimulus with 25 mg/mL peptide in the presence of IL-2 (20 ng/mL). Culture supernatants were collected after 48 hr incubation and stored at À80°C. IFN-g secretion in the culture supernatants was measured by ELISA (PeproTech, Rocky Hill, NJ, USA) in 96-well ELISA plates (Nunc MaxiSorp) as per the manufacturer's instructions (17) . Finally, absorbance of each well was recorded at 405 nm using a microplate reader (Tecan, M€ annedorf, Switzerland), taking 630 nm as the reference wavelength,. IFN-g production was expressed as fold changes in cytokine release as follows: Fold change ¼ absorbance of peptide stimulated cells/ unstimulated cells
Proliferation assay
To measure peptide-induced proliferation of PBMC, cells harvested from unstimulated and stimulated wells on Day 10 were distributed and stimulated as discussed for IFN-g measurement. At the end of Day 6, MTT (0.5 mg/mL) was added to the cultures, which were then incubated again for 4 hr (18, 19) . The purple formazan crystals thus formed were solubilised in 100 mL DMSO. Finally, absorbance of each well was recorded at 570 nm using a microplate reader, taking 630 nm as the reference wavelength. Proliferation was calculated in terms of SI as follows: SI ¼ absorbance of the peptide stimulated cells/unstimulated cells
Statistical analysis
Statistical significance of the data for PBMC proliferation and extracellular IFN-g release was analysed by the one tailed t-test for unpaired data using GraphPad prism 6 for Windows. P values < 0.05 were considered to denote statistical significance.
RESULTS
Allergenicity and toxicity analysis of tested peptides
Peptides derived from the internal M1 protein are considered to be good candidates for development of a universal influenza vaccine. An essential aspect of vaccine development is assessment of allergenicity and toxicity of the vaccine candidates. None of the peptides under consideration were found to possess any allergenicity or toxicity.
Tested peptides induce INF-g release
Peptide-mediated T cell activation of PBMC was measured in terms of IFN-g production. IFN-g released by stimulated PBMC cultures was measured by ELISA 12 days after initial seeding. The cultures were restimulated on Days 4, 7 and 10. Of the M1 peptides, LQAYQKRMGVQMQR (P M 3) showed IFN-g production in all six tested samples with significantly high production in five of them (Fig. 1c) . Of the seven samples screened, three showed positive responses with significant IFN-g production in the case of ILGFVFTLTV-PSERGLQRRRF (P M 1), whereas four of five positive responders showed significantly strong secretion of the cytokine on stimulation with LIRHENRMVLASTTAKA (P M 2) (Fig. 1a,b) . Concanavalin A, which was used as a positive control, triggered stronger IFN-g responses in all the samples (mean AE SEM and range of fold increase equal 1.94 AE 0.17 and 1.3-3.8, respectively). Thus, P M 3 elicited the strongest immunogenicity of the three M1 peptides.
Tested peptides induce lymphocyte proliferation
MTT assays were performed to measure peptide-induced proliferation of PBMC isolated from healthy donors. This colorimetric assay relies on the ability of mitochondrial dehydrogenases in the metabolic active cells to reduce MTT. Proliferation was assayed 16 days after initial seeding. All seven samples showed significant proliferative responses to P M 1 stimulation (Fig. 2a) . Similarly, all seven responded positively to P M 2 stimulation, six of them showing significant proliferation (Fig. 2b) . Thus, P M 1 and P M 2 peptides exhibited the strongest immune responses. All four positive responders against P M 3 peptide induced significant proliferation as compared to the unstimulated cells (Fig. 2c) . 
DISCUSSION
Antigenic variations have impeded development of a universal or broadly reactive influenza vaccine. Current strain-specific influenza vaccines impart humoral immunity, which does not reliably neutralize mutant or heterosubtypic influenza viruses. However, this development paved the way for the concept of an alternative vaccine approach based for cellular immunity against influenza. Substantial evidence from various animal and human studies suggests that T cells, specifically CD8 þ T cells, correlate positively with cross-subtype immunity during secondary influenza A virus infection (20) . CD4 þ T cells both promote B cell responses and activation and proliferation of CD8 þ T cells. In agreement with this, an influenza vaccine based on the highly conserved T cell epitopes and capable of eliciting cellular immune responses would potentially obviate the need for annual reformulation of vaccines. Numerous peptides for eliciting T cellmediated immunity have been identified (21) (22) (23) (24) . M1 protein is an attractive target for a universal vaccine against influenza virus because it is a highly conserved internal influenza protein. M1 plays vital roles the in influenza virus life cycle, namely maintaining the architecture of the influenza virus, nucleocytoplasmic transport of newly formed viral ribonucleoproteins and promotion of viral budding. Further, M1 protein is reportedly a potent activator of human myeloid dendritic cells, which efficiently present it to M1-specific CD8 þ T lymphocytes (25) . In light of these facts, three highly conserved peptides of H1N1 M1 protein, namely ILGFVFTLTV-PSERGLQRRRF (P M 1), LIRHENRMVLASTTAKA (P M 2) and LQAYQKRMGVQMQR (P M 3), which contain multiple CD4 þ and CD8 þ T cell epitopes, were evaluated for their allergenicity, toxicity and in vitro immunogenicity in healthy PBMC.
Immunotherapy is often associated with a high incidence of adverse effects related to allergenicity of vaccines and other therapeutic agents. Therefore, it is important to identify and eliminate potential allergens. Peptide-based therapeutic agents have frequently been linked to allergic reactions and toxicity (26, 27) . Therefore, the three tested M1 peptides were analyzed for allergenicity and toxicity using in silico prediction tools and all three were predicted to be safe as influenza vaccine targets. Secretion of IFN-g along with some other cytokines marks the onset of antigen-specific T cell proliferation and differentiation. Hence, accurate detection of secreted cytokines provides an insight into the immunogenic capacity of a peptide. ELISA was employed to measure IFN-g secreted upon peptide stimulation of PBMC (28, 29) . Rather than measuring cytokine-positive/cytokine secreting cells, ELISA provides direct evidence of immunogenicity (30) . In the present study, seven different PBMC samples were stimulated with P M 1 and P M 2 peptides and six PBMC samples were stimulated with P M 3 peptide. Peptide P M 3 resulted in IFN-g production in all six samples tested, whereas P M 1 and P M 2 showed IFN-g production in three and five samples, respectively.
The MTT assay has been reported as a sensitive and safe non-radioactive assay for measuring PBMC proliferation by various researchers (18, 31) . Proliferation of the three peptides under consideration in the present study was significantly greater than with unstimulated cells. P M 1 and P M 2 showed PBMC proliferation in all seven samples, whereas peptide P M 3 showed proliferation in four of six samples. Thus, we found that all three peptides are able to mount immune response in terms of proliferation as well as IFN-g release. Minor variations in responses to the peptides were observed in different samples because PBMC are heterogeneous and HLA haplotypes vary between individuals because of extensive HLA polymorphism.
M1 protein is regarded as an important internal influenza protein that is highly conserved. 118 T cell epitopes of M1 protein of H1N1, H3N2 and H2N2 subtypes had been recognised in humans up until 03 January 2017 (32) . Large peptides containing M1 peptides P M 2 and P M 3, namely TNPLIRHENRMVLASTTAKA and LENLQAYQKRMGVQMQR, reportedly elicited immunogenic response in earlier studies (33) (34) (35) . Small peptides that share identity with P M 1 peptides like LGFVFTLTVPSERG and ILGFVFTLTV have been reported to induce T cell proliferation and IFN-g secretion (36, 37) ; however, the immunogenicity of the complete P M 1 peptide has not been reported as such. Considering the fact that these M1 peptides are conserved among various subtypes of influenza A virus that are known to infect humans, these peptides appear to be perfect candidates for a broadly reactive influenza vaccine (12) . Peptides that can bind to an array of HLA alleles are ideal for the development of a T cell epitopebased vaccine candidates because they have the potential to elicit immunogenic response in different populations worldwide. Both sequence-based prediction and structure-based molecular docking approaches have shown that M1 peptides containing mutiple T cell epitopes bind to multiple HLA alleles (12) .
Current influenza vaccine regimes are based on traditional formulations like trivalent and quadrivalent inactivated vaccines and live attenuated vaccines. These vaccines are composed of inactivated or attenuated strains of circulating influenza A and B virus (38) . Various other vaccines based on recombinant HA and cell-culture derived inactivated vaccine have been licensed in the recent past (39) . These strain-specific influenza virus vaccines need to be reformulated almost every year because of antigenic drift and variation between different age groups in their efficacy. Mismatches between vaccine and circulating strains result in incompetent neutralizing antibody responses. In such cases, internal and more conserved influenza proteins potentially induce some cross-reactive T-cell memory and provide protection, thus having a positive influence on immune responses against natural infection. According to one study, a trivalent inactivated vaccine that was formulated for induction of serotype-specific antibody responses against surface glycoproteins, also contained M1 protein, which induces subtype cross-reactive CD8 þ T-cell responses in some vaccinated individuals (40) . Thus, to induce broad protection, current vaccine designs need to be modified to include the conserved T cell epitopes that are present across influenza virus subtypes.
Long synthetic immunogenic peptides are devoid of all risks associated with reversion, genetic recombination or integration. Also, large scale synthesis and production with desired purity, modification, storage and transportation (in freeze dried form) of peptides are relatively easy as compared with traditional vaccines. Further, peptides can easily be modified chemically or combined with adjuvants or carrier molecules to enhance their delivery to immune cells (41) . Several concepts of influenza vaccines based on peptides of M1 protein that elicit T cell-mediated immune response are currently under clinical trial. Vaccine FP-01.1, which is undergoing phase II clinical trials, contains six long peptides from internal influenza protein M1, NP and polymerase basic proteins (PB1 and PB2) (24) . Another peptidebased vaccine preparation called Flu-V is composed of four long peptides from M1, M2, and NP protein with Montanide ISA 51VG adjuvant. This concept has also entered phase II trials (42, 43) . All these studies support immunogenic peptides containing multiple T cell epitopes as strong candidates for influenza vaccine development.
To conclude, three highly conserved, non-allergic and non-toxic synthetic M1 peptides, ILGFVFTLTV-PSERGLQRRRF (P M 1), LIRHENRMVLASTTAKA (P M 2) and LQAYQKRMGVQMQR (P M 3), containing multiple overlapping CD4 þ and CD8 þ T cell epitopes are able to elicit immune response in terms of IFN-g release and proliferation. These peptides have earlier been reported to be highly conserved (>90%) in H1N1, H3N2, H5N1 and H2N2 isolated from humans and bind array of class I and II HLA alleles. Hence, these peptides offer great potential as broadly reactive T cell-based vaccine candidates in the fight against both epidemic and pandemic influenza. 
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